- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01796639
Retrospective Study of Long-term Survival and Related Factors Among Kidney Transplant Recipients in China (REACH)
The primary objective of this study is to evaluate graft survival and recipient survival among kidney transplant recipients in China, and also to analyze possible factors related to patient and graft survival.
The secondary objective is to evaluate several secondary outcomes among kidney transplant recipients, such as average creatinine value, acute rejection episodes, NODM, incidence of BKV infection etc. At the same time analyze possible impact factors related to these secondary outcomes.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Renal transplantation is the choice for patients with end-stage renal disease. In the past two decades, progress in surgical procedure, medical care, and immunosuppression have significantly improved the short-term results of organ transplantation. Nevertheless, grafts continue to fail over time, these improvements in immunosuppression and reduced incidence of acute rejection episodes have had only minimal effects on chronic allograft dysfunction and late graft loss. Long-term patient's death and graft failure are the main limitations for a better performance of renal transplant programs.
Multiple factors have been shown to affect the outcome of renal transplantation. These include demographic characteristics such as race and ethnicity, pretransplantation dialysis course, the timing of the transplantation,and the patients' co morbidities. Patient response to the transplantation procedure (e.g., delayed graft function, acute rejection, and acute tubular necrosis) is strongly associated with the long-term prognosis. In the last decade, with the increase of immunosuppressive agents in our therapeutic arsenal, several attempts have been made to improve graft performance. However, the majority of trials aiming to avoid calcineurin inhibitor (CNI)-related nephrotoxicity only reported short-term data. Also, and because of the lack of assessment of the role of the different ethiopathogenic factors that lead to graft damage, just avoiding CNI-related nephrotoxicity may be an oversimplification of the problem in the prevention of graft attrition.
There are many studies which have evaluated the long-term outcomes of graft and patient survival and have analyzed multiple relative factors. Unfortunately, such data in Chinese population are lacking. Meanwhile, the situation in China is somewhat different with others, such as race, the dosage of immunosuppressant and so on. A better characterization of the weight of immune and non-immune factors responsible for graft damage may help us to improve the outcomes in transplant recipients. Studies derived from well-designed and well-performed patient registries can provide a real world view of clinical practice, patient outcomes, safety, and comparative effectiveness and cost effectiveness. The goal of this project is to analyze retrospective data collected by disease registry, then to evaluate the graft and recipient outcomes of kidney transplants and relative impact factors.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Beijing
-
Beijing, Beijing, China, 100034
- Peking University First Hospital
-
Beijing, Beijing, China, 100853
- Chinese PLA General Hospital
-
Beijing, Beijing, China, 100000
- The 309th Hospital of Chinese People's Liberation Army
-
Beijing, Beijing, China, 100020
- Beijing Chaoyang Hospital
-
Beijing, Beijing, China, 100050
- Beijing Friendship Hospital
-
-
Fujian
-
Fuzhou, Fujian, China, 350025
- Fuzhou General hospital of Nanjing Military Command
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- The First Affiliated Hospital Sun Yat-Sen University
-
Guangzhou, Guangdong, China, 510599
- Nanfang Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Tongji Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410000
- The second Xiangya Hospital of Central South University
-
-
Liaoning
-
Shenyang, Liaoning, China
- Shenyang Military General Hospital
-
-
Shandong
-
Jinan, Shandong, China, 250000
- Jinan Military General Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Zhongshan Hospital Fudan University
-
Shanghai, Shanghai, China, 200080
- Shanghai First People's Hospital
-
-
Shanxi
-
Xian, Shanxi, China, 710061
- First Affiliated Hospital Of Medical College of Xian Jiaotong University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital,Sichuan University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- The First Affiliated Hospital, Zhejiang University
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Kidney transplant recipients
- Received a transplant from Jan 1,1995 to Dec 31, 2007, only including those with living donor grafts
- Age: 18-75 years
Exclusion Criteria:
- Multiple-organ transplant recipients
- Patients records with missing information in 12 months post-transplantation
- Patients who did not have the information regarding their maintenance immunosuppressive therapy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Cohort
- Tijdsperspectieven: Retrospectief
Cohorten en interventies
Groep / Cohort |
---|
kidney transplantation patients with living-donor grafts
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Graft survival
Tijdsspanne: 5-year
|
Graft survival, measured as the time between kidney transplant and the failure of the graft.
|
5-year
|
Recipient survival
Tijdsspanne: 5-year
|
measured as the time between the most recent kidney transplant and the patient's death.
Graft outcome was censored at the earliest of the following events and was analyzed as days to graft failure or censor: loss to follow-up, patient death.
|
5-year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Average creatinine value
Tijdsspanne: 5 years
|
5 years
|
The rate of acute rejection episodes
Tijdsspanne: 5 years
|
5 years
|
The incidence of BPAR and its severity
Tijdsspanne: 5 years
|
5 years
|
The incidence of NODM
Tijdsspanne: 5 years
|
5 years
|
The incidence of infection
Tijdsspanne: 5 years
|
5 years
|
The incidence of biopsy proven CNIs nephrotoxicity
Tijdsspanne: 5 years
|
5 years
|
The rate of posttransplantation malignancies
Tijdsspanne: 5 years
|
5 years
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- COLO400ACN02
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Niertransplantatie
-
Children's Oncology GroupNational Cancer Institute (NCI)Actief, niet wervendStadium I Nier Wilms-tumor | Stadium II Kidney Wilms-tumor | Stadium III Kidney Wilms-tumor | Stadium IV Kidney Wilms-tumor | Volwassen Nier Wilms-tumor | Beckwith-Wiedemann-syndroom | Kidney Wilms-tumor | Diffuse hyperplastische perilobar nefroblastomatose | Rhabdoïde tumor van de nier | Stadium V Kidney...Verenigde Staten, Canada, Australië, Nieuw-Zeeland, Puerto Rico, Israël
-
Children's Oncology GroupNational Cancer Institute (NCI)VoltooidTerugkerend nierneoplasma bij kinderen | Stadium I Nier Wilms-tumor | Stadium II Kidney Wilms-tumor | Stadium III Kidney Wilms-tumor | Stadium IV Kidney Wilms-tumorVerenigde Staten
-
Children's Oncology GroupNog niet aan het wervenStadium I Nier Wilms-tumor | Stadium II Kidney Wilms-tumor | Stadium III Kidney Wilms-tumor | Stadium IV Kidney Wilms-tumor
-
CAMC Health SystemOnbekendAKI (Acute Kidney Injury) als gevolg van traumaVerenigde Staten
-
Children's Oncology GroupNational Cancer Institute (NCI)WervingStadium II Kidney Wilms-tumor | Stadium III Kidney Wilms-tumor | Stadium IV Kidney Wilms-tumor | Terugkerende Nier Wilms-tumor | Anaplastische Nier Wilms-tumorVerenigde Staten, Canada, Puerto Rico, Australië, Nieuw-Zeeland, Saoedi-Arabië
-
Ain Shams UniversityVoltooidAKI (Acute Kidney Injury) als gevolg van traumaEgypte
-
Children's Oncology GroupNational Cancer Institute (NCI)Actief, niet wervendStadium III Kidney Wilms-tumor | Stadium IV Kidney Wilms-tumorVerenigde Staten, Canada, Australië, Nieuw-Zeeland, Puerto Rico, Israël, Zwitserland
-
Children's Oncology GroupNational Cancer Institute (NCI)Actief, niet wervendStadium I Nier Wilms-tumor | Stadium II Kidney Wilms-tumor | Stadium III Kidney Wilms-tumorVerenigde Staten, Canada, Australië, Nieuw-Zeeland, Puerto Rico, Israël, Zwitserland